Pricing & Sizes
Ships sealed and lyophilized — stable for years at room temperature, supplied as lyophilised powder. Free shipping on every order, no minimum. Every batch ships with its lab report. Reports come from third-party labs including Janoshik, Freedom Diagnostics and Chromate, most verifiable through the lab's own public portal. Ask and we will send the report for your batch.
Reconstitution — bacteriostatic water: 20mg vial reconstituted at 2mL gives 10mg/mL. These are concentrations, calculated from vial content and diluent volume. They describe the solution, not a dose.
Bought separately, BPC-157 10mg is $48. Wolverine is $95 and adds 10mg of TB-500, which is not sold as a standalone vial.
Email To OrderAlso Available in These Blends
In Plain English
Think of a repair crew arriving at a damaged site. BPC-157 is the material — the signal that tells injured tissue to start rebuilding, and the most-studied healing peptide in animal research. TB-500 is the logistics. Repair cells have to physically travel through tissue to reach the place that needs them, and that is the job TB-500 is meant to handle. Material and delivery. That is the reason people run the two together rather than either one alone.
What people use it for. This is the recovery stack — injuries, joint, and tendon issues, and general repair after hard training. It is the most requested combination in the range.
What to know before you buy. If you are also looking at GLOW or KLOW, both of those already contain BPC-157 and TB-500. Running Wolverine on top of either one just doubles the same two peptides rather than adding anything to the stack. Pick one rather than layering them — it will save you money.
What It's Studied For
| Research area | What that rests on |
|---|---|
| Injury and strain recovery | The most requested recovery pairing; BPC-157 brings the deepest animal literature in the category |
| Tendon and joint support | Improved healing across multiple animal injury models for BPC-157 |
| Training recovery | Two repair signals acting through separate mechanisms |
| Convenience | One vial instead of two, at the ratio most people run anyway |
The left column lists the research areas this compound is investigated in; the right column states what that rests on. These are published research findings, not proven outcomes or treatment claims, and nothing here is a recommendation. Sold for laboratory research use only.
At a Glance
- Components
- BPC-157 and TB-500, typically at a 1:1 ratio
- Rationale
- Two repair signals acting through different mechanisms — angiogenesis and growth factor modulation (BPC-157) alongside actin regulation and cell migration (TB-500)
- Evidence
- BPC-157 has an extensive animal literature; TB-500 has essentially none of its own. The blend as a combination has never been formally studied
- Regulatory (US)
- Neither component is FDA-approved. Both were recommended for 503A listing on 23 July 2026; no FDA action has been taken on either
- Format
- 20mg vial (10mg + 10mg)
Regulatory status
On 23 July 2026 the FDA Pharmacy Compounding Advisory Committee voted 8-6-1 to recommend both BPC-157 and TB-500 for the Section 503A bulk drug substances list. That vote is advisory only. As of 17 August 2026 the FDA has taken no action on it, has not opened rulemaking, and has not moved the substance to the interim Category 1 list. FDA’s own scientific reviewers had recommended against all seven peptides; the committee voted against staff on six consecutive votes, so the usual assumption that a PCAC recommendation predicts the agency’s decision is weaker here than normal. Several outlets have reported this as the FDA “clearing”, “approving” or “adding” these peptides to the bulks list. That is inaccurate. Nothing has been added and nothing is legally cleared.
How the Components Compare
| Component | What it adds | What it does not do |
|---|---|---|
| BPC-157 | The deepest evidence base of the pair — 100+ animal studies across tendon, ligament, muscle, gut, skin, and bone. Also the only one of the two with any gut application | Does not address skin, collagen or inflammation directly. No completed human trial |
| TB-500 | Adds a separate repair mechanism — cell migration and tissue remodelling rather than angiogenesis, so it is complementary rather than duplicative | Has no direct research of its own; supporting work belongs to the larger parent protein. Nothing for inflammation or skin |
What You Are Actually Buying
The two components sit at very different points on the evidence scale, and a blend sheet that averages them would be misleading. Read them separately:
| Component | Evidence position | Main caveat |
|---|---|---|
| BPC-157 | 100+ animal studies over three decades; 1 of 36 published studies involved humans | No completed randomised controlled trial; a phase 2 trial in hamstring strain (NCT07437547) began recruiting February 2026 |
| TB-500 | FDA stated in July 2026 that there were no studies on TB-500 itself; a phase 1/2 trial (NCT07487363) has since begun recruiting | Supportive research belongs to Tβ4, a larger protein; vendor sequences vary; unresolved theoretical cancer question |
Sourcing note
Because “TB-500” is a common name rather than a defined substance, the COA matters more for this blend than for most. Verify the stated sequence and molecular weight for the TB-500 component specifically, not just the total peptide content.
Stacking Consideration
Wolverine overlaps directly with the GLOW and KLOW blends, both of which also contain BPC-157 and TB-500. Running Wolverine alongside either one doubles those two components rather than adding anything new. If you are moving between them, replacing is cleaner than stacking — both for dose control and because it keeps the variable clean if you are trying to judge what is working.
The bottom line
A pairing that makes sense on mechanism: one component with a deep animal literature, one that directs where repair is sent. The July 2026 recommendation improves the odds of a legal compounding pathway eventually existing. It says nothing about the blend itself, which has not been studied as a blend.